Hydroxyurea Should NOT Be Used for Rheumatoid Arthritis
Hydroxyurea is not an approved or recommended treatment for rheumatoid arthritis and should not be used for this indication. The FDA-approved indications for hydroxyurea are limited to resistant chronic myeloid leukemia and locally advanced squamous cell carcinomas of the head and neck 1. Current rheumatoid arthritis treatment guidelines make no mention of hydroxyurea as a therapeutic option.
Why Hydroxyurea Is Not Appropriate for RA
Guideline-Based Treatment Hierarchy
The most recent 2026 PANLAR guidelines and 2021 ACR guidelines establish a clear treatment algorithm for RA that does not include hydroxyurea 2, 3:
First-line therapy: Conventional synthetic DMARDs (csDMARDs)
- Methotrexate is the preferred initial choice
- Alternatives include leflunomide, sulfasalazine, and hydroxychloroquine (note: hydroxychloroquine, NOT hydroxyurea)
Second-line therapy: If methotrexate monotherapy fails
- Triple therapy (methotrexate + sulfasalazine + hydroxychloroquine)
- Biologic DMARDs (TNF inhibitors, IL-6 inhibitors, B-cell depleting agents)
- Targeted synthetic DMARDs (JAK inhibitors)
The Evidence Gap
The only research on hydroxyurea for RA consists of:
- A small 1995 open-label pilot study with just 5 patients (4 completed), showing minimal and inconsistent benefits 4
- Case reports where hydroxyurea was used to treat underlying hematologic conditions (myelofibrosis, essential thrombocytosis) that coincidentally occurred with RA 5, 6
This evidence is insufficient to support hydroxyurea use for RA treatment. The 1995 study was preliminary, uncontrolled, and the authors themselves concluded that "confirmation will require further testing by a randomized double blind placebo controlled trial" 4. No such trial has been conducted in the nearly 30 years since.
Critical Safety Concerns
Hydroxyurea carries significant risks that make it inappropriate for RA:
- Myelosuppression - bone marrow suppression is a major toxicity 1
- Carcinogenic potential - increased mammary tumors in animal studies 1
- Mutagenic and clastogenic effects - causes DNA damage 1
- Teratogenic effects - causes fetal harm 1
These risks are acceptable only when treating life-threatening conditions like leukemia, not for managing RA where multiple safer, proven alternatives exist.
The Correct Approach
For DMARD-naive RA patients with active disease, start with methotrexate as the anchor therapy 2. Optimize methotrexate dosing (consider subcutaneous administration if GI intolerance occurs) before declaring treatment failure 2. If inadequate response, escalate to combination csDMARDs or add biologic/targeted synthetic DMARDs according to established treatment algorithms 2, 3.
Common pitfall: Confusing hydroxychloroquine (an antimalarial DMARD commonly used in RA) with hydroxyurea (a chemotherapy agent). These are completely different medications with different mechanisms, indications, and safety profiles.